12
05 '16
Boundary Capital has announced its latest investment in Toxibact, a disruptive technology which has the potential to kill a wide range of microorganisms including bacteria and fungi with little prospect of them being able to develop resistance. Toxibact has a novel potential antimicrobial therapy for the treatment of all bacteria – both ‘gram positive’ and…